Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.
Biochemical markers of bone metabolism (bone markers) are used increasingly to monitor response to therapy and may be predictors of bone loss and fractures. The relationship between fracture rates, which differ between countries, and the rate of bone turnover has not been examined. Therefore, we explored the geographic variability of bone turnover in a selected, healthy study population of 619 postmenopausal women, ages 40-61, participating in a clinical trial of raloxifene hydrochloride for osteoporosis prevention. The subjects were distributed among 38 investigative sites in 10 countries (9-211 subjects/country) on four continents (North America, n = 277, Europe, n = 168, Australia, n = 125, and Africa, n = 49). Specimens for serum osteocalcin (OC), bone-specific alkaline phosphatase (BSAP), and urine type I collagen fragment/urinary creatinine ratio (CTX) were handled in a uniform fashion and assayed in a central laboratory. Mean levels of OC (P < 0.001), BSAP (P = 0. 006), and CTX (P < 0.001) varied significantly by country (ANOVA), with the lowest values typically in German and Spanish subjects and the highest in American and Canadian subjects. The consistent pattern and wide ranges of mean bone marker values (OC 1.6-fold, BSAP 1.7-fold, CTX 3.1-fold) between countries suggest clinically significant differences in bone turnover. Geographic differences in bone markers were not explained by the determined potential confounders of age, years posthysterectomy, total serum cholesterol, and serum follicle stimulating hormone (FSH). We conclude that bone marker values vary substantially by country in this selected study population, suggesting systematic geographic differences in bone metabolism that potentially relate to osteoporotic fracture rates.
Cohen
F J
FJ
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.
Eckert
S
S
Mitlak
B H
BH
D000328:Adult; D000349:Africa; D000469:Alkaline Phosphatase / Q000097:blood*; D000704:Analysis of Variance; D001315:Australia; D015415:Biomarkers / Q000097:blood / Q000652:urine; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism*; D003094:Collagen / Q000652:urine*; D024042:Collagen Type I; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005060:Europe; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000517:prevention & control / Q000652:urine; D010455:Peptides / Q000652:urine*; D010880:Piperidines / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride
D015415:Biomarkers; D024042:Collagen Type I; D004965:Estrogen Antagonists; D010455:Peptides; D010880:Piperidines; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D020849:Raloxifene Hydrochloride; D003094:Collagen; D000469:Alkaline Phosphatase